Neovascular Age-related Macular Degeneration
Conditions
Keywords
zoledronic acid, anti-VEGF, anti-vascular endothelial growth factor, adjuvant therapy, AMD
Brief summary
A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).
Detailed description
This is a one-year, randomized, controlled pilot study. A total of 40 treatment-naïve nAMD patients will be allocated 1:1 to receive an intravenous infusion of either zoledronic acid (ZA) 5 mg or placebo at baseline and after 26 weeks as adjuvant therapy to intravitreal anti-VEGF injections in accordance with a treat and extend algorithm; bevacizumab is the first-line treatment, and refractory eyes are converted to aflibercept. The participants will be recruited among patients admitted to the Department of Ophthalmology at Oslo University Hospital (OUH). The department is the largest provider of retinal care in Norway and serves a local community of almost one million people, which makes it well-suited for recruitment. Administration of ZA or placebo will take place at Pilestredet Park Specialist Centre, an endocrinology clinic in Oslo with particular interest in treatment of osteoporosis. The Clinical Trial Unit at OUH will monitor the study.
Interventions
Zoledronic acid
DRUGPlacebos
NaCl 0.9%
Sponsors
Oslo University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Active, treatment-naïve neovascular AMD in the study eye, intraretinal or subretinal fluid involving the fovea centre on optical coherence tomography (OCT), and evidence of choroidal neovascularization on fluorescein angiography (FA) and/or OCT angiography (OCT-A). 2. Age ≥50 years 3. Best-corrected visual acuity (BCVA) between 0.1 and 1.0 logMAR 4. Menopausal for at least one year 5. Only one eye per patient will be recruited for the study. If both eyes are eligible for the study, the eye with the wors best-corrected Visual acuity (BCVA) will be selected as the study eye. 6. Subjects must give written informed consent before any study related procedures are performed
Exclusion criteria
1. Lesions comprising more than 50% blood or fibrosis involving the fovea centre 2. Polypoidal choroidal vasculopathy (PCV) - indocyanine green (ICG) angiography is performed at the discretion of the investigator on clinical suspicion of PCV 3. Presence of other ocular disease causing concurrent vision loss 4. Presence of ocular disease making intravitreal treatment contraindicated (e.g. current ocular or periocular infection, active uveitis or uncontrolled glaucoma/intraocular pressure ≥ 25 mmHg) 5. Systemic anti-vascular endothelial growth factor (anti-VEGF) or bisphosphonate treatment within one year preceding the initial study treatment 6. Confirmed or suspected active malignancy 7. Other factors (i.e. lack of cooperation) that, in the opinion of the investigator, can interfere with the study protocol 8. Known or suspected hypersensitivity to any of the trial products 9. Hypocalcemia (total Ca \< 2.15 mmol/L) 10. Renal impairment (estimated ClCR \< 35 ml/min).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change from baseline in best-corrected visual acuity (BCVA) after 52 weeks. | 52 weeks | To assess the change in best-corrected visual acuity measured by logMAR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with a change in BCVA of 0.3 logMAR or more after 52 weeks. | 52 weeks | Number of patients with a change in BCVA of 0.3 logMAR or more after 52 weeks. |
| Proportion of patients with refractory nAMD after 52 weeks. | 52 weeks | Proportion of patients with refractory nAMD after 52 weeks. |
| The number of anti-VEGF intravitreal injections given after 52 weeks | 52 weeks | To assess the number of anti-VEGF injections needed during 52 weeks of treatment. |
| Mean change from baseline in Central retinal thickness (CRT) after 52 weeks. | 52 weeks | Mean change from baseline in Central retinal thickness (CRT) after 52 weeks.To assess the proportion of patients with a considerable change in visual function |
| Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femoral fracture, endophthalmitis or orbital, scleral, or serious intraocular inflammation (grade 4 aqueous cells/FLARE). | 52 weeks | Proportion of patients experiencing adverse events of special interest (ESI): osteonecrosis of the jaw or atypical femoral fracture, endophthalmitis or orbital, scleral, or serious intraocular inflammation (grade 4 aqueous cells/FLARE). |
| EQ 5D score (ranging from 0-1; 0 designates perfect health and NEI-VFQ-25 score (ranging from 0 to 100 where 100 reflects best vision-specific health). | 52 weeks | EQ 5D score (ranging from 0-1; 0 designates perfect health and NEI-VFQ-25 score (ranging from 0 to 100 where 100 reflects best vision-specific health). |
Countries
Norway
Outcome results
None listed